HS research update (2026-10-01): What’s new on PubMed?

Publication overview

This update includes 22 PubMed publications with abstracts from the monitoring window 2026-09-17 to 2026-10-01. The most common themes are biologicsBiologic: A class of medications derived from living cells that target specific components of the inflammatory process. For Acne Inversa, biologics such as adalimumab and secukinumab are used when other treatments are insufficient.BiologicA class of medications derived from living cells that target specific components of the inflammatory process. For Acne Inversa, biologics such as adalimumab and secukinumab are used when other treatments are insufficient.Read more in the glossary, pain, wound care, quality of life, comorbiditiesComorbidity: An additional condition existing alongside the primary disease. Acne Inversa is frequently associated with comorbidities including metabolic syndrome, inflammatory bowel disease, spondyloarthritis, and depression.ComorbidityAn additional condition existing alongside the primary disease. Acne Inversa is frequently associated with comorbidities including metabolic syndrome, inflammatory bowel disease, spondyloarthritis, and depression.Read more in the glossary.

• Compared with the previous update: not automatically assessed.
• No guideline/NEJM/Lancet-style high-impact matches with abstracts in this window.
• This is a research overview, not a guideline update or medical recommendation.

Top highlights

The most useful signal this round is not a single treatment instruction. It is what researchers are looking at more closely: wound healing after procedures, possible new anti-inflammatory approaches, care quality, and comorbidities.

• Hidradenitis Suppurativa: Part of a Tetrad of Follicular OcclusionFollicular Occlusion: The blockage of hair follicles is considered a key starting point in the development of Acne Inversa. When a follicle becomes obstructed, inflammation can spread deep into tissue, leading to nodules, abscesses, and sinus tracts.Follicular OcclusionThe blockage of hair follicles is considered a key starting point in the development of Acne Inversa. When a follicle becomes obstructed, inflammation can spread deep into tissue, leading to nodules, abscesses, and sinus tracts.Read more in the glossary Disorders.: The abstract describes a new publication. In practical terms, it focuses on this question or finding: UNLABELLED: Follicular occlusion disorders (FOD) represent a tetrad of chronic, recurrent inflammatory conditions united by a common pathophysiologic mechanism: follicular hyperkeratosisHyperkeratosis: An excess buildup of keratin in the outer layers of skin or inside a follicle. Hyperkeratosis of the follicular wall physically blocks the follicle, setting the first step of Acne Inversa pathology in motion.HyperkeratosisAn excess buildup of keratin in the outer layers of skin or inside a follicle. Hyperkeratosis of the follicular wall physically blocks the follicle, setting the first step of Acne Inversa pathology in motion.Read more in the glossary leading to occlusion, rupture,… What makes it notable here is that it approaches HS through biologics, quality of life, pain, wound care, surgery. The main limitation to keep in mind is: From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full. (PMID 42759045)
• Pathogenesis of hidradenitis suppurativa: From susceptibility to chronicity.: The abstract describes a new publication. In practical terms, it focuses on this question or finding: Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease characterized by painful nodulesNodule: A firm, palpable lump deep in tissue. Nodules can be painful and may progress to abscesses. They are among the typical early signs of Acne Inversa.NoduleA firm, palpable lump deep in tissue. Nodules can be painful and may progress to abscesses. They are among the typical early signs of Acne Inversa.Read more in the glossary, abscessesAbscess: An inflamed cavity or swelling containing pus or fluid. In hidradenitis suppurativa, abscesses can form as part of the inflammatory disease process and do not automatically mean that a bacterial infection is present. Secondary bacterial infection can occur and may require separate medical assessment. In Acne Inversa, abscesses occur mainly in the armpits, groin, and other skin folds.AbscessAn inflamed cavity or swelling containing pus or fluid. In hidradenitis suppurativa, abscesses can form as part of the inflammatory disease process and do not automatically mean that a bacterial infection is present. Secondary bacterial infection can occur and may require separate medical assessment. In Acne Inversa, abscesses occur mainly in the armpits, groin, and other skin folds.Read more in the glossary, draining tunnelsDraining Tunnel: A sinus tract or fistula actively leaking fluid (serous, purulent, or blood-tinged) to the surface. Draining tunnels carry the heaviest weight in modern HS severity scores because they signal long-standing, structurally damaged disease.Draining TunnelA sinus tract or fistula actively leaking fluid (serous, purulent, or blood-tinged) to the surface. Draining tunnels carry the heaviest weight in modern HS severity scores because they signal long-standing, structurally damaged disease.Read more in the glossary and scarring, with substantial effects on quality of life. Although the the… What makes it notable here is that it approaches HS through quality of life, biologics, pain. The main limitation to keep in mind is: From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full. (PMID 42786922)
• Hidradenitis Suppurativa from Preconception to Lactation: Clinical Treatment Decision-Making Review.: The abstract describes a new publication. In practical terms, it focuses on this question or finding: Hidradenitis suppurativa is a chronic, inflammatory skin disease that predominantly affects women of reproductive age and may require continuous therapeutic control during pregnancy and lactation. This review summariz… What makes it notable here is that it approaches HS through biologics, jak inhibitor, comorbidities. The main limitation to keep in mind is: From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full. (PMID 42768237)
• A Silent Killer in an Unlikely Place: Necrotizing Fasciitis of the Breast.: The abstract describes a new publication. In practical terms, it focuses on this question or finding: Primary necrotizing fasciitis (NF) of the breast is a rare, life-threatening soft tissue infection that is frequently misdiagnosed due to its non-specific early presentation and uncommon anatomical location.Objective:… What makes it notable here is that it approaches HS through biologics, pain, wound care. The main limitation to keep in mind is: From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full. (PMID 42764423)
• IL-17 treatment and side-effect management: This paper focuses on mucocutaneous candidiasis during bimekizumabBimekizumab: A monoclonal antibody blocking both IL-17A and IL-17F. Approved by the FDA on 20 November 2024 as the first IL-17A and IL-17F inhibitor for adults with moderate-to-severe HS; approved by the EMA in April 2024. Brand name: Bimzelx®.BimekizumabA monoclonal antibody blocking both IL-17A and IL-17F. Approved by the FDA on 20 November 2024 as the first IL-17A and IL-17F inhibitor for adults with moderate-to-severe HS; approved by the EMA in April 2024. Brand name: Bimzelx®.Read more in the glossary therapy for HS. The new angle is practical: how prevention and early management of a known IL-17-pathway adverse event might affect tolerability and treatment persistence. (PMID 42812940)

Featured publication

The featured paper is Efficacy and safety of two interleukin-17Interleukin-17 (IL-17): Inflammatory cytokines (IL-17A and IL-17F) that drive neutrophil recruitment and tissue damage in Acne Inversa. IL-17A is blocked by secukinumab; both IL-17A and IL-17F are blocked by bimekizumab.Interleukin-17 (IL-17)Inflammatory cytokines (IL-17A and IL-17F) that drive neutrophil recruitment and tissue damage in Acne Inversa. IL-17A is blocked by secukinumab; both IL-17A and IL-17F are blocked by bimekizumab.Read more in the glossary inhibitors (bimekizumab and secukinumabSecukinumab: A biologic drug that inhibits the inflammatory messenger interleukin-17A (IL-17A). Secukinumab was approved as the second biologic for treating Acne Inversa and is available under the brand name Cosentyx®.SecukinumabA biologic drug that inhibits the inflammatory messenger interleukin-17A (IL-17A). Secukinumab was approved as the second biologic for treating Acne Inversa and is available under the brand name Cosentyx®.Read more in the glossary) in the management of hidradenitis suppurativa: a systematic review and meta-analysis of randomized controlled trials. in Skin health and disease (PMID 42812940). The abstract mainly says this: Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that primarily affects the intertriginous regions, causing manifestations such as inflammatory nodules, abscesses and scarring. OBJECTIVES: To sys…

Why it stands out: it connects to the priority themes biologics, pain and shows what HS researchers are trying to clarify right now. For readers, it matters because it gives one concrete example of how the field is framing a practical question or possible mechanism. The main limitation is that Its strength depends on the quality and comparability of the included studies, and an abstract does not expose every methodological weakness.

What this may mean for patients (carefully, no advice)

If you live with HS, research updates can help you make sense of what’s being studied — for example which outcomes (pain, quality of life) researchers measure, or which comorbidities are increasingly part of the conversation.

But even when a study sounds promising, it usually does not tell you what is right for you personally. Consider using new findings as questions for your next appointment (e.g., “What are realistic goals for me?” or “Which related conditions should we keep an eye on?”), not as instructions.

What we don’t know / limitations

• This update includes only PubMed items with an abstract (without an abstract, safe summarization is limited).
• Studies vary widely (design, populations, outcome measures).
• This update provides no treatment advice and cannot assess individual risk.

Important: decisions belong in clinician conversations

This article is an editorial overview and is not medically reviewed. If something here worries or interests you, use it as a conversation starter for your next appointment. Decisions should always be made with qualified healthcare professionals.

FAQ

Why are there only a few new publications here?

This format is deliberately strict: it includes only new PubMed items from the monitoring window that have an abstract and were not already covered in earlier posts.

Does a new paper mean my treatment should change?

No. A single publication can be useful to know about, but it is usually not enough to guide decisions for one specific person.

Why emphasize limitations so much?

Because abstracts show only part of the picture. Study design, patient population, endpoints, and follow-up all matter before results can be interpreted responsibly.

Sources & original papers

Each point below maps to an original source (PubMed link, plus DOI/PMCID when available).